Speaker(s): 
Alexander Chang, MD - Geisinger Primary Care. Disclosures include Novartis, Bayer, Novo Nordisk, Boeringer-Ingelheim.

Moderator(s): 
Angela Esherick, RDN, LDN, CDCES, Geisinger Nutrition Services, has nothing to disclose.

Learning Objectives: 
At the conclusion of this session, the participant should be able to: 

• Describe the significance of CKD in diabetes

• Explain the benefits and risks of recommended medication classes for patients with diabetes and CKD 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:
The Planning Committee consisting of Stacy Coolbaugh, MBA, RDN, LDN; Angela Esherick, RDN, LDN, CDCES; Adriene Zook, PharmD, RPH, Dan Huston, DNP, RN, BC-ADM, and Angela Zammit have no identified disclosures. 

CE Committee Member/Content Reviewers Alison Mowery, DNP, CRNP and Timothy Murphy, MD have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 
This presentation/content is HIPPA compliant.